New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Andrew Sindone

Prof Andrew Sindone

An Update on Heart Failure in Primary Care

Dr Gabby Mahoney

Dr Gabby Mahoney

Allergen Introduction – Practical Tips for GPs

Prof Kim Delbaere

Prof Kim Delbaere

Falls Prevention – A Practical, Evidence-Based Update on What Really Works

Dr Stephanie Daly

Dr Stephanie Daly

The New Dementia Test and How they Fit Into the Assessment and Management of the Patient with Cognitive Concerns

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 1 January 1970